Clinical trial
H-9926-LCH III: Treatment Protocol of the Third International Study for…
NCT00488605 · University of New Mexico, Other · Withdrawn
Key facts
| NCT number | NCT00488605 |
|---|---|
| Title | H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis |
| Official title | H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis |
| Lead sponsor | University of New Mexico, Other |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Prednisone, Vinblastin, 6-mercaptopuroine, Leucovorin, Methotrexate, Vinblastine |
| Enrollment | 0 |
| Start date | Aug 1, 2023 |
| Primary completion | Aug 1, 2023 |
| Completion | Aug 1, 2023 |
| First posted | Jun 20, 2007 |
| Last update posted | Aug 3, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: